Sign Up
|
Sign In
Home
US Market
UK Market
News
My Portfolio
Forex
Forum
Cockpit
EuroTrader
Home
»
World
»
North America
»
United States
»
Biotechnology
»
Gilead Sciences Inc
Gilead Sciences Inc
GILD
(NASDAQ)
Overview
Discussions
Advanced chart
News
Historical data
Recommendations
To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed.
Industry
:
Health Care
Sector
:
Pharmaceuticals & Biotechnology
$
50.89
Updated
00:30:00
Change %
1.9%
Change
0.9500
Volume
5,692,882
High
$
50.92
Low
$
50.00
Open
$ 50.03
Prev close
$ 49.94
# of shares
-
Market cap
-
Intraday
Market closed
Tech analysis
Market is closed, opens at 14:30
Price development
Latest
1 week
1 month
3 mon
6 mon
1 year
50.89
-1.9%
-0.2%
14.3%
31.3%
24.2%
Insufficient flash player version
News about Gilead Sciences Inc
Subscribe To RSS Feed
Local
International
Announcements
11 May
UPDATE: FDA Panel Backs Gilead's HIV 'Quad' Medicine
11 May
FDA Panel Backs Gilead's HIV 'Quad' Medicine
11 May
WSJ BLOG/Health: A.M. Vitals: Extended Breast Feeding, Obesity Drug and Heart Devices
09 May
WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid; Regulators Like Preventive HIV Drug
09 May
FDA: Safety Of Proposed Gilead HIV Drug "Generally Acceptable"
08 May
FDA Appears To Support Gilead HIV Drug As Prevention Tool
07 May
WSJ BLOG/Health: A.M. Vitals: Autism Shift Won't Leave Kids Behind, Study Says
26 April
Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins
26 April
TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks
25 April
TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks
24 March
Gilead fija precio de obligaciones senior no garantizadas por valor de $1.000 millones
24 March
Gilead fixe le prix de ses billets de premier rang non garantis à 1 milliard USD
24 March
Gilead stelt prijs vast van $1 miljard aan ‘senior unsecured’ schuldpapieren
24 March
L’essai clinique de Phase III de l’elvitégravir expérimental de Gilead atteint l’objectif primaire de 48 semaines
24 March
Fase III klinische trial van Gileads onderzoeksgeneesmiddel elvitegravir voldoet aan primaire doelstelling voor eerste 48 weken
24 March
La sperimentazione clinica di Fase III sull’agente antiretrovirale sperimentale di Gilead Elvitegravir raggiunge l’obiettivo pri
23 March
El ensayo clínico de Fase III del fármaco en fase de investigación de Gilead, elvitegravir, supera el objetivo principal de 48 s
11 February
Gilead Sciences vuelve a presentar a la FDA solicitud de nuevo fármaco para el régimen de único comprimido de Truvada® y TMC278
11 February
Gilead Sciences deposita nuovamente la domanda di approvazione di nuovo farmaco presso l’ente statunitense preposto al controllo
11 February
Gilead Sciences soumet à nouveau une demande de nouveau médicament auprès de l’agence américaine des médicaments pour le schéma
No news for this instrument
More news
Company profile
No description
Version: LiveBranchBuild_20120516.1 - EUROWEB1 - 2012-05-22 02:14:56 - 2012-05-22 01:14:56 - 1000 - Website: OKAY